Vunakizumab not checked

Hengrui · SHR-1314

FollowEvery change as it happens, and a Monday email
Stage
in China
Next date
Phase 4 trial completes
Trials
8 active
18 in total · 6 in the EU
Targets
 

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
Tested for
Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Children and Adolescents Aged 6 to 18 With Moderate-to-Severe Plaque Psoriasis, Active Non-radiographic Axial Spondyloarthritis
Main trialPhase 4
“This is a prospective, single-arm, multicenter, Phase IV study of 1564 patients with moderate-to-severe chronic plaque psoriasis to evaluate the efficacy and safety of Vunakizumab in patients with moderate-to-severe plaque psoriasis who have converted from other biologics. To explore the efficacy of difficult-to-treat area, patient satisfaction and patient-reported outcomes (PRO).”In the company’s words, NCT06779097 on ClinicalTrials.gov
Other names
SHR-1314

Other drugs for Moderate to Severe Plaque Psoriasis

All 41 drugs for Moderate to Severe Plaque Psoriasis

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials18

TrialPhaseCompletesWhat it tests
Phase 4Not yet recruiting Mar 2027 Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis
Phase 3Active, not recruiting 5 Jun 2026 A Study of the Efficacy and Safety of SHR-1314 for Adult Active Psoriatic Arthritis
Phase 3Not yet recruiting Jul 2026 The Efficacy and Safety of SHR-1314 in the Treatment of Pediatric Patients of Age 6 to <18 Years With Moderate to Severe Plaque Psoriasis
Phase 3Recruiting Feb 2028 A Trial of SHR-1314 Injection in Adult Patients With Active Non-radiographic Axial Spondyloarthritis
Phase 3Unknown 30 Aug 2023 Efficacy 、Safety and PK of SHR-1314 in Patients With Moderate-to-Severe Plaque Psoriasis
Phase 2/3Completed 3 Nov 2023 Efficacy and Safety of SHR-1314 in Patients With Active Ankylosing Spondylitis
Phase 2Unknown 25 Dec 2021 A Phase II Study to Evaluate the Efficacy and Safety of SHR-1314 in Lupus Nephritis
Phase 2Terminated 22 Aug 2023 Efficacy and Safety of SHR-1314 by Subcutaneous Injection in Active Moderate to Severe Graves' Orbitopathy Patients
Phase 2Completed 5 Jun 2024 Study of the Effectiveness and Safety of SHR-1314 for Psoriatic Arthritis
Phase 1/2Completed 31 Aug 2020 Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis
Phase 1Completed 14 Jan 2020 Safety, Tolerability and PK of SHR1314 in axSpA
Phase 1Completed 13 May 2024 A Clinical Study to Compare the Safety and Pharmacokinetics of SHR-1314 Injection in Healthy Subjects at Different Specifications Devices
Phase 3Authorised not given A Phase III double-blind placebo-controlled Randomised Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients
Phase 3Authorised not given A randomised, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of PQ Birch in subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induced by birch pollen exposure
Phase 3/4Ended not given The effects of the manipulation of 5-HT, DA and NA on exercise-induced fatigue and brain activation
Phase 2Not authorised not given A RAndomised Placebo Controlled Trial - to Explore the Efficacy and Mechanism of Action of Tezepelumab in EGPA- RACE-MATE
Phase 2Authorised not given Tocotrienol and bevacizumab in metastatic colorectal cancer. A randomized phase II marker trial
Phase 3Authorised not given Rifampin-free regimen versus rifampin-containing regimen in the treatment of staphylococcal prosthetic valve endocarditis: a multicenter randomized controlled non-inferiority study (RIFREE)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Vunakizumab

Following is part of Solo: you see every change to Vunakizumab the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in